• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jochen H Lorch, MD, MSc


  • Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, Hammerman PS.
    Genomic analysis of metastatic cutaneous squamous cell carcinoma.
    Clin Cancer Res. 2015 Mar 15;21(6):1447-56.
  • Guze K, Pawluk HC, Short M, Zeng H, Lorch J, Norris C, Sonis S.
    Pilot study: Raman spectroscopy in differentiating premalignant and malignant oral lesions from normal mucosa and benign lesions in humans.
    Head Neck. 2014 Feb 15.
  • Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI.
    Trastuzumab for the treatment of salivary duct carcinoma.
    Oncologist. 2013;18(3):294-300.
  • Hanna GJ, Haddad RI, Lorch JH.
    Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future?.
    Oncologist. 2013;18(3):288-93.
  • Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M.
    Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
    Lancet Oncol. 2013 Mar;14(3):257-64.
  • Lin CI, Whang EE, Lorch JH, Ruan DT.
    Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Surgery. 2012 Dec;152(6):1142-9.
  • Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR, .
    Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
    Lancet Oncol. 2011 Feb;12(2):153-9.
  • Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, Jiang X, Price BD, Moore FD, Ruan DT.
    Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer.
    Mol Cancer Res. 2010 Sep;8(9):1217-26.
  • Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, Wirth L, Lorch J, Andreozzi B, Annino D, Posner MR.
    Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
    J Clin Oncol. 2009 Sep 20;27(27):4448-53.
  • Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV, Sarlis N, Lorch J, Cullen KJ.
    Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.
    Cancer Prev Res (Phila Pa). 2009 Sep;2(9):776-81.
  • Lorch JH,Posner MR,Wirth LJ,Haddad RI.
    Seeking alternative biological therapies: the future of targeted molecular treatment.
    Oral Oncol. 2009 Apr-May;45(4-5):447-53. Review.
  • Lorch JH,Posner MR,Wirth LJ,Haddad RI.
    Induction chemotherapy in locally advanced head and neck cancer: a new standard of care?.
    Hematol Oncol Clin North Am. 2008 Dec;22(6):1155-63, viii. Review.